相关实验视频
Updated: Mar 16, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
怀孕期间高血糖症的早期治疗的证据
1Gleneagles Hospital, Singapore.
概括
怀孕早期高血糖症,与妊娠糖尿病 (GDM) 不同,与不良结果有关. 然而,目前的证据并不总是支持早期诊断和治疗改善母亲和新生儿健康.
科学领域:
- 产科和妇科 产科和妇科
- 内分泌学 在内分泌学.
- 孕产妇和胎儿医学 孕产妇和胎儿医学
背景情况:
- 孕期糖尿病 (GDM) 通常在怀孕后期 (24-28周) 诊断出来.
- 怀孕早期的高血糖症是一种较温和的葡萄糖不耐受症,可能会在标准GDM查之前出现.
- 即使是轻微的早期高血糖也与不良的孕产妇和新生儿结局有关.
研究的目的:
- 为了区分传统的GDM与怀孕早期的高血糖症.
- 审查早期失糖症的诊断标准和生理机制.
- 评估早期诊断和治疗母亲和胎儿结局的临床益处.
主要方法:
- 对机理学和流行病学数据的审查.
- 检查GDM和早期高血糖症的当前诊断框架.
- 随机对照试验的分析和早期干预的元分析.
主要成果:
- 早期的孕产妇高血糖是生物学上可能影响孕产妇和胎儿的结果.
- 现有的随机对照试验和元分析并没有始终显示早期诊断和治疗改善了结果.
- 目前的证据基础存在重大局限性.
结论:
- 虽然怀孕早期高血糖症与风险有关,但缺乏通过早期诊断和治疗改善孕产妇/新生儿结果的有力证据.
- 需要进一步的研究来澄清早期怀孕高血糖症管理的好处和最佳策略.
- 目前研究的局限性凸显了未来研究的需要,这些研究重点关注特定的血糖值和干预措施.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
5.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones
813
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
813
Diabetes: Management and Pharmacotherapy
1.3K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.3K
Hypoglycemia and Glucagon
1.2K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.2K
Pathophysiology of Diabetes
4.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.1K
Oral Hypoglycemic Agents: Glinides
821
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
821

